Global minimal residual disease (MRD) testing market will reach $ 2,858.1 million by 2031, growing by 12.4% annually over 2021-2031, driven by the rising prevalence of hematological malignancy and cancer, the aging population, technological advancements in diagnostics and therapies due to increasing R&D investment, and the growing healthcare expenditure.
Highlighted with 86 tables and 87 figures, this 170-page report “Global Minimal Residual Disease (MRD) Testing Market 2021-2031 by Offering (Services, Test Kits & Consumables), Application (NHL, MM, ALL, CLL, AML, CML, HL, Solid Tumor), Technology (Flow Cytometry, PCR, NGS, Others), End User (Hospitals and Clinics, Research Institutions, Diagnostic Laboratories, Others), and Region: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire global minimal residual disease (MRD) testing market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2018-2021 and provides forecast from 2022 till 2031 with 2021 as the base year.
The trend and outlook of global market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19 and Russia-Ukraine conflict. The balanced (most likely) projection is used to quantify global minimal residual disease (MRD) testing market in every aspect of the classification from perspectives of Offering, Application, Technology, End User, and Region.
For each aforementioned region and country, detailed analysis and data for annual revenue ($ mn) are available for 2021-2031. The breakdown of all regional markets by country and split of national markets by Application, Technology, and End User over the forecast years are also included.
The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
Highlighted with 86 tables and 87 figures, this 170-page report “Global Minimal Residual Disease (MRD) Testing Market 2021-2031 by Offering (Services, Test Kits & Consumables), Application (NHL, MM, ALL, CLL, AML, CML, HL, Solid Tumor), Technology (Flow Cytometry, PCR, NGS, Others), End User (Hospitals and Clinics, Research Institutions, Diagnostic Laboratories, Others), and Region: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire global minimal residual disease (MRD) testing market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2018-2021 and provides forecast from 2022 till 2031 with 2021 as the base year.
In-depth qualitative analyses include identification and investigation of the following aspects:
- Market Structure
- Growth Drivers
- Restraints and Challenges
- Emerging Product Trends & Market Opportunities
- Porter’s Five Forces
The trend and outlook of global market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19 and Russia-Ukraine conflict. The balanced (most likely) projection is used to quantify global minimal residual disease (MRD) testing market in every aspect of the classification from perspectives of Offering, Application, Technology, End User, and Region.
Based on Offering, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.
- Services
- Test Kits & Consumables
Based on Application, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.
- Non-Hodgkin's Lymphoma (NHL)
- DLBCL
- Marginal Zone Lymphoma
- Follicular Lymphoma
- Peripheral T-cell Lymphoma
- Mantle Cell Lymphoma
- Other NHLs
- Multiple Myeloma (MM)
- Acute Lymphoblastic Leukemia (ALL)
- Chronic Lymphoblastic Leukemia (CLL)
- Acute Myeloid Leukemia (AML)
- Chronic Myeloid Leukemia (CML)
- Hodgkin's Lymphoma (HL)
- Solid Tumor
- Other Applications
By Technology, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.
- Flow Cytometry
- Polymerase Chain Reaction (PCR)
- Next-Generation Sequencing (NGS)
- Other Technologies
By End User, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.
- Hospitals and Clinics
- Research Institutions
- Diagnostic Laboratories
- Other End Users
Geographically, the following regions together with the listed national/local markets are fully investigated:
- North America (U.S., Canada, and Mexico)
- Europe (Germany, UK, France, Spain, Italy, Netherlands, Rest of Europe; Rest of Europe is further segmented into Russia, Switzerland, Poland, Sweden, Belgium, Austria, Ireland, Norway, Denmark, and Finland)
- APAC (Japan, China, South Korea, Australia, India, and Rest of APAC; Rest of APAC is further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, Taiwan, and Philippines)
- South America (Brazil, Chile, Argentina, Rest of South America)
- MEA (UAE, Saudi Arabia, South Africa, Other Nations)
For each aforementioned region and country, detailed analysis and data for annual revenue ($ mn) are available for 2021-2031. The breakdown of all regional markets by country and split of national markets by Application, Technology, and End User over the forecast years are also included.
The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Selected Key Players:
- Adaptive Biotechnologies Corporation
- ArcherDX, Inc. (Invitae Corporation)
- Arup Laboratories
- Asuragen Inc.
- Bio-Rad Laboratories, Inc.
- Cergentis B.V.
- Guardant Health
- ICON plc
- Inivata Ltd.
- Invivoscribe, Inc.
- Laboratory Corporation of America Holdings
- Mission Bio, Inc.
- Natera, Inc.
- NeoGenomics Laboratories, Inc.
- Opko Health, Inc.
- Quest Diagnostics Incorporated
- Sysmex Corporation
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
Frequently Asked Questions about the Global Minimal Residual Disease Testing Market
What is the estimated value of the Global Minimal Residual Disease Testing Market?
What is the growth rate of the Global Minimal Residual Disease Testing Market?
What is the forecasted size of the Global Minimal Residual Disease Testing Market?
Who are the key companies in the Global Minimal Residual Disease Testing Market?
| Report Attribute | Details |
|---|---|
| No. of Pages | 170 |
| Published | May 2022 |
| Forecast Period | 2021 - 2031 |
| Estimated Market Value ( USD | $ 884.6 Million |
| Forecasted Market Value ( USD | $ 2858.1 Million |
| Compound Annual Growth Rate | 12.4% |
| Regions Covered | Global |
Table of Contents
1 Introduction1.1 Industry Definition and Research Scope
1.1.1 Industry Definition
1.1.2 Research Scope
1.2 Research Methodology
1.2.1 Overview of Market Research Methodology
1.2.2 Market Assumption
1.2.3 Secondary Data
1.2.4 Primary Data
1.2.5 Data Filtration and Model Design
1.2.6 Market Size/Share Estimation
1.2.7 Research Limitations
1.3 Executive Summary
2 Market Overview and Dynamics
2.1 Market Size and Forecast
2.1.1 Impact of COVID-19 on World Economy
2.1.2 Impact of COVID-19 on the Market
2.2 Major Growth Drivers
2.3 Market Restraints and Challenges
2.4 Emerging Opportunities and Market Trends
2.5 Porter’s Fiver Forces Analysis
3 Segmentation of Global Market by Offering
3.1 Market Overview by Offering
3.2 Services
3.3 Test Kits & Consumables
4 Segmentation of Global Market by Application
4.1 Market Overview by Application
4.2 Non-Hodgkin’s Lymphoma (NHL)
4.2.1 DLBCL
4.2.2 Marginal Zone Lymphoma
4.2.3 Follicular Lymphoma
4.2.4 Peripheral T-cell Lymphoma
4.2.5 Mantle Cell Lymphoma
4.2.6 Other NHLs
4.3 Multiple Myeloma (MM)
4.4 Acute Lymphoblastic Leukemia (ALL)
4.5 Chronic Lymphoblastic Leukemia (CLL)
4.6 Acute Myeloid Leukemia (AML)
4.7 Chronic Myeloid Leukemia (CML)
4.8 Hodgkin’s Lymphoma (HL)
4.9 Solid Tumor
4.10 Other Applications
5 Segmentation of Global Market by Technology
5.1 Market Overview by Technology
5.2 Flow Cytometry
5.3 Polymerase Chain Reaction (PCR)
5.4 Next-Generation Sequencing (NGS)
5.5 Other Technologies
6 Segmentation of Global Market by End User
6.1 Market Overview by End User
6.2 Hospitals and Clinics
6.3 Research Institutions
6.4 Diagnostic Laboratories
6.5 Other End Users
7 Segmentation of Global Market by Region
7.1 Geographic Market Overview 2021-2031
7.2 North America Market 2021-2031 by Country
7.2.1 Overview of North America Market
7.2.2 U.S.
7.2.3 Canada
7.2.4 Mexico
7.3 European Market 2021-2031 by Country
7.3.1 Overview of European Market
7.3.2 Germany
7.3.3 U.K.
7.3.4 France
7.3.5 Spain
7.3.6 Italy
7.3.7 Netherlands
7.3.8 Rest of European Market
7.4 Asia-Pacific Market 2021-2031 by Country
7.4.1 Overview of Asia-Pacific Market
7.4.2 Japan
7.4.3 China
7.4.4 Australia
7.4.5 India
7.4.6 South Korea
7.4.7 Rest of APAC Region
7.5 South America Market 2021-2031 by Country
7.5.1 Argentina
7.5.2 Brazil
7.5.3 Chile
7.5.4 Rest of South America Market
7.6 MEA Market 2021-2031 by Country
7.6.1 UAE
7.6.2 Saudi Arabia
7.6.3 South Africa
7.6.4 Other National Markets
8 Competitive Landscape
8.1 Overview of Key Vendors
8.2 New Product Launch, Partnership, Investment, and M&A
8.3 Company Profiles
- Adaptive Biotechnologies Corporation
- ArcherDX, Inc. (Invitae Corporation)
- Arup Laboratories
- Asuragen Inc.
- Bio-Rad Laboratories, Inc.
- Cergentis B.V.
- Guardant Health
- ICON plc
- Inivata Ltd.
- Invivoscribe, Inc.
- Laboratory Corporation of America Holdings
- Mission Bio, Inc.
- Natera, Inc.
- NeoGenomics Laboratories, Inc.
- Opko Health, Inc.
- Quest Diagnostics Incorporated
- Sysmex Corporation
List of TablesTable 1. Snapshot of Global Minimal Residual Disease Testing Market in Balanced Perspective, 2021-2031
Table 2. World Economic Outlook, 2021-2031
Table 3. World Health Spending by Region, $ bn, 2013-2020
Table 4. Main Product Trends and Market Opportunities in Global Minimal Residual Disease Testing Market
Table 5. Global Minimal Residual Disease Testing Market by Offering, 2021-2031, $ mn
Table 6. Global Minimal Residual Disease Testing Market by Application, 2021-2031, $ mn
Table 7. Global Minimal Residual Disease Testing Market: Non-Hodgkin’s Lymphoma (NHL) by Type, 2021-2031, $ mn
Table 8. Global Minimal Residual Disease Testing Market by Technology, 2021-2031, $ mn
Table 9. Main Vendors and Products of Flow Cytometry Technology
Table 10. Main Vendors and Products of Polymerase Chain Reaction (PCR) Technology
Table 11. Main Vendors and Products of Next-Generation Sequencing (NGS) Technology
Table 12. Global Minimal Residual Disease Testing Market by End User, 2021-2031, $ mn
Table 13. Global Minimal Residual Disease Testing Market by Region, 2021-2031, $ mn
Table 14. Leading National Minimal Residual Disease Testing Market, 2021 and 2031, $ mn
Table 15. North America Minimal Residual Disease Testing Market by Country, 2021-2031, $ mn
Table 16. U.S. Minimal Residual Disease Testing Market by Application, 2021-2031, $ mn
Table 17. U.S. Minimal Residual Disease Testing Market by Technology, 2021-2031, $ mn
Table 18. U.S. Minimal Residual Disease Testing Market by End User, 2021-2031, $ mn
Table 19. Canada Minimal Residual Disease Testing Market by Application, 2021-2031, $ mn
Table 20. Canada Minimal Residual Disease Testing Market by Technology, 2021-2031, $ mn
Table 21. Canada Minimal Residual Disease Testing Market by End User, 2021-2031, $ mn
Table 22. Mexico Minimal Residual Disease Testing Market by Application, 2021-2031, $ mn
Table 23. Mexico Minimal Residual Disease Testing Market by Technology, 2021-2031, $ mn
Table 24. Mexico Minimal Residual Disease Testing Market by End User, 2021-2031, $ mn
Table 25. Europe Minimal Residual Disease Testing Market by Country, 2021-2031, $ mn
Table 26. Germany Minimal Residual Disease Testing Market by Application, 2021-2031, $ mn
Table 27. Germany Minimal Residual Disease Testing Market by Technology, 2021-2031, $ mn
Table 28. Germany Minimal Residual Disease Testing Market by End User, 2021-2031, $ mn
Table 29. U.K. Minimal Residual Disease Testing Market by Application, 2021-2031, $ mn
Table 30. U.K. Minimal Residual Disease Testing Market by Technology, 2021-2031, $ mn
Table 31. U.K. Minimal Residual Disease Testing Market by End User, 2021-2031, $ mn
Table 32. France Minimal Residual Disease Testing Market by Application, 2021-2031, $ mn
Table 33. France Minimal Residual Disease Testing Market by Technology, 2021-2031, $ mn
Table 34. France Minimal Residual Disease Testing Market by End User, 2021-2031, $ mn
Table 35. Spain Minimal Residual Disease Testing Market by Application, 2021-2031, $ mn
Table 36. Spain Minimal Residual Disease Testing Market by Technology, 2021-2031, $ mn
Table 37. Spain Minimal Residual Disease Testing Market by End User, 2021-2031, $ mn
Table 38. Italy Minimal Residual Disease Testing Market by Application, 2021-2031, $ mn
Table 39. Italy Minimal Residual Disease Testing Market by Technology, 2021-2031, $ mn
Table 40. Italy Minimal Residual Disease Testing Market by End User, 2021-2031, $ mn
Table 41. Netherlands Minimal Residual Disease Testing Market by Application, 2021-2031, $ mn
Table 42. Netherlands Minimal Residual Disease Testing Market by Technology, 2021-2031, $ mn
Table 43. Netherlands Minimal Residual Disease Testing Market by End User, 2021-2031, $ mn
Table 44. Minimal Residual Disease Testing Market in Rest of Europe by Country, 2021-2031, $ mn
Table 45. APAC Minimal Residual Disease Testing Market by Country, 2021-2031, $ mn
Table 46. Japan Minimal Residual Disease Testing Market by Application, 2021-2031, $ mn
Table 47. Japan Minimal Residual Disease Testing Market by Technology, 2021-2031, $ mn
Table 48. Japan Minimal Residual Disease Testing Market by End User, 2021-2031, $ mn
Table 49. China Minimal Residual Disease Testing Market by Application, 2021-2031, $ mn
Table 50. China Minimal Residual Disease Testing Market by Technology, 2021-2031, $ mn
Table 51. China Minimal Residual Disease Testing Market by End User, 2021-2031, $ mn
Table 52. Australia Minimal Residual Disease Testing Market by Application, 2021-2031, $ mn
Table 53. Australia Minimal Residual Disease Testing Market by Technology, 2021-2031, $ mn
Table 54. Australia Minimal Residual Disease Testing Market by End User, 2021-2031, $ mn
Table 55. India Minimal Residual Disease Testing Market by Application, 2021-2031, $ mn
Table 56. India Minimal Residual Disease Testing Market by Technology, 2021-2031, $ mn
Table 57. India Minimal Residual Disease Testing Market by End User, 2021-2031, $ mn
Table 58. South Korea Minimal Residual Disease Testing Market by Application, 2021-2031, $ mn
Table 59. South Korea Minimal Residual Disease Testing Market by Technology, 2021-2031, $ mn
Table 60. South Korea Minimal Residual Disease Testing Market by End User, 2021-2031, $ mn
Table 61. Minimal Residual Disease Testing Market in Rest of APAC by Country/Region, 2021-2031, $ mn
Table 62. South America Minimal Residual Disease Testing Market by Country, 2021-2031, $ mn
Table 63. Argentina Minimal Residual Disease Testing Market by Application, 2021-2031, $ mn
Table 64. Argentina Minimal Residual Disease Testing Market by Technology, 2021-2031, $ mn
Table 65. Argentina Minimal Residual Disease Testing Market by End User, 2021-2031, $ mn
Table 66. Brazil Minimal Residual Disease Testing Market by Application, 2021-2031, $ mn
Table 67. Brazil Minimal Residual Disease Testing Market by Technology, 2021-2031, $ mn
Table 68. Brazil Minimal Residual Disease Testing Market by End User, 2021-2031, $ mn
Table 69. Chile Minimal Residual Disease Testing Market by Application, 2021-2031, $ mn
Table 70. Chile Minimal Residual Disease Testing Market by Technology, 2021-2031, $ mn
Table 71. Chile Minimal Residual Disease Testing Market by End User, 2021-2031, $ mn
Table 72. MEA Minimal Residual Disease Testing Market by Country, 2021-2031, $ mn
Table 73. UAE Minimal Residual Disease Testing Market by Application, 2021-2031, $ mn
Table 74. UAE Minimal Residual Disease Testing Market by Technology, 2021-2031, $ mn
Table 75. UAE Minimal Residual Disease Testing Market by End User, 2021-2031, $ mn
Table 76. Saudi Arabia Minimal Residual Disease Testing Market by Application, 2021-2031, $ mn
Table 77. Saudi Arabia Minimal Residual Disease Testing Market by Technology, 2021-2031, $ mn
Table 78. Saudi Arabia Minimal Residual Disease Testing Market by End User, 2021-2031, $ mn
Table 79. South Africa Minimal Residual Disease Testing Market by Application, 2021-2031, $ mn
Table 80. South Africa Minimal Residual Disease Testing Market by Technology, 2021-2031, $ mn
Table 81. South Africa Minimal Residual Disease Testing Market by End User, 2021-2031, $ mn
Table 82. Breakdown of World Market by Key Vendor, 2021, %
Table 83. Approved and Launched MRD Testing Products of Key Vendors
Table 84. Adaptive Biotechnologies Corporation: Company Snapshot
Table 85. Adaptive Biotechnologies Corporation: Business Segmentation
Table 86. Adaptive Biotechnologies Corporation: Product PortfolioList of FiguresFigure 1. Research Method Flow Chart
Figure 2. Bottom-up Approach and Top-down Approach for Market Estimation
Figure 3. Global Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2021-2031
Figure 4. Global Minimal Residual Disease Testing Market, 2021-2031, $ mn
Figure 5. Impact of COVID-19 on Business
Figure 6. Primary Drivers and Impact Factors of Global Minimal Residual Disease Testing Market
Figure 7. World Number of Deaths from Cancers in 201
Figure 8. Worldwide Geriatric Population (60 years and above) by Regions, 2015 & 2030, million
Figure 9. World Population 65 and Over, % of Total Population, 1950-2060
Figure 10. Primary Restraints and Impact Factors of Global Minimal Residual Disease Testing Market
Figure 11. Investment Opportunity Analysis
Figure 12. Porter’s Five Forces Analysis of Global Minimal Residual Disease Testing Market
Figure 13. Breakdown of Global Minimal Residual Disease Testing Market by Offering, 2021-2031, % of Revenue
Figure 14. Global Addressable Market Cap in 2022-2031 by Offering, Value ($ mn) and Share (%)
Figure 15. Global Minimal Residual Disease Testing Market by Offering: Services, 2021-2031, $ mn
Figure 16. Global Minimal Residual Disease Testing Market by Offering: Test Kits & Consumables, 2021-2031, $ mn
Figure 17. Breakdown of Global Minimal Residual Disease Testing Market by Application, 2021-2031, % of Sales Revenue
Figure 18. Global Addressable Market Cap in 2022-2031 by Application, Value ($ mn) and Share (%)
Figure 19. Global Minimal Residual Disease Testing Market by Application: Non-Hodgkin’s Lymphoma (NHL), 2021-2031, $ mn
Figure 20. Global Minimal Residual Disease Testing Market by Non-Hodgkin’s Lymphoma (NHL): DLBCL, 2021-2031, $ mn
Figure 21. Global Minimal Residual Disease Testing Market by Non-Hodgkin’s Lymphoma (NHL): Marginal Zone Lymphoma, 2021-2031, $ mn
Figure 22. Global Minimal Residual Disease Testing Market by Non-Hodgkin’s Lymphoma (NHL): Follicular Lymphoma, 2021-2031, $ mn
Figure 23. Global Minimal Residual Disease Testing Market by Non-Hodgkin’s Lymphoma (NHL): Peripheral T-cell Lymphoma, 2021-2031, $ mn
Figure 24. Global Minimal Residual Disease Testing Market by Non-Hodgkin’s Lymphoma (NHL): Mantle Cell Lymphoma, 2021-2031, $ mn
Figure 25. Global Minimal Residual Disease Testing Market by Non-Hodgkin’s Lymphoma (NHL): Other NHLs, 2021-2031, $ mn
Figure 26. Global Minimal Residual Disease Testing Market by Application: Multiple Myeloma (MM), 2021-2031, $ mn
Figure 27. Global Minimal Residual Disease Testing Market by Application: Acute Lymphoblastic Leukemia (ALL), 2021-2031, $ mn
Figure 28. Global Minimal Residual Disease Testing Market by Application: Chronic Lymphoblastic Leukemia (CLL), 2021-2031, $ mn
Figure 29. Global Minimal Residual Disease Testing Market by Application: Acute Myeloid Leukemia (AML), 2021-2031, $ mn
Figure 30. Global Minimal Residual Disease Testing Market by Application: Chronic Myeloid Leukemia (CML), 2021-2031, $ mn
Figure 31. Global Minimal Residual Disease Testing Market by Application: Hodgkin’s Lymphoma (HL), 2021-2031, $ mn
Figure 32. Global Minimal Residual Disease Testing Market by Application: Solid Tumor, 2021-2031, $ mn
Figure 33. Global Minimal Residual Disease Testing Market by Application: Other Applications, 2021-2031, $ mn
Figure 34. Breakdown of Global Minimal Residual Disease Testing Market by Technology, 2021-2031, % of Sales Revenue
Figure 35. Global Addressable Market Cap in 2022-2031 by Technology, Value ($ mn) and Share (%)
Figure 36. Global Minimal Residual Disease Testing Market by Technology: Flow Cytometry, 2021-2031, $ mn
Figure 37. Global Minimal Residual Disease Testing Market by Technology: Polymerase Chain Reaction (PCR), 2021-2031, $ mn
Figure 38. Global Minimal Residual Disease Testing Market by Technology: Next-Generation Sequencing (NGS), 2021-2031, $ mn
Figure 39. Global Minimal Residual Disease Testing Market by Technology: Other Technologies, 2021-2031, $ mn
Figure 40. Breakdown of Global Minimal Residual Disease Testing Market by End User, 2021-2031, % of Revenue
Figure 41. Global Addressable Market Cap in 2022-2031 by End User, Value ($ mn) and Share (%)
Figure 42. Global Minimal Residual Disease Testing Market by End User: Hospitals and Clinics, 2021-2031, $ mn
Figure 43. Global Minimal Residual Disease Testing Market by End User: Research Institutions, 2021-2031, $ mn
Figure 44. Global Minimal Residual Disease Testing Market by End User: Diagnostic Laboratories, 2021-2031, $ mn
Figure 45. Global Minimal Residual Disease Testing Market by End User: Other End Users, 2021-2031, $ mn
Figure 46. Global Market Snapshot by Region
Figure 47. Geographic Spread of Worldwide Minimal Residual Disease Testing Market, 2021-2031, % of Sales Revenue
Figure 48. Global Addressable Market Cap in 2022-2031 by Region, Value ($ mn) and Share (%)
Figure 49. North American Minimal Residual Disease Testing Market, 2021-2031, $ mn
Figure 50. Breakdown of North America Minimal Residual Disease Testing Market by Country, 2021 and 2031, % of Revenue
Figure 51. Contribution to North America 2022-2031 Cumulative Market by Country, Value ($ mn) and Share (%)
Figure 52. U.S. Minimal Residual Disease Testing Market, 2021-2031, $ mn
Figure 53. Canada Minimal Residual Disease Testing Market, 2021-2031, $ mn
Figure 54. Minimal Residual Disease Testing Market in Mexico, 2021-2031, $ mn
Figure 55. European Minimal Residual Disease Testing Market, 2021-2031, $ mn
Figure 56. Breakdown of European Minimal Residual Disease Testing Market by Country, 2021 and 2031, % of Revenue
Figure 57. Contribution to Europe 2022-2031 Cumulative Market by Country, Value ($ mn) and Share (%)
Figure 58. Minimal Residual Disease Testing Market in Germany, 2021-2031, $ mn
Figure 59. Minimal Residual Disease Testing Market in U.K., 2021-2031, $ mn
Figure 60. Minimal Residual Disease Testing Market in France, 2021-2031, $ mn
Figure 61. Minimal Residual Disease Testing Market in Spain, 2021-2031, $ mn
Figure 62. Minimal Residual Disease Testing Market in Italy, 2021-2031, $ mn
Figure 63. Minimal Residual Disease Testing Market in Netherlands, 2021-2031, $ mn
Figure 64. Minimal Residual Disease Testing Market in Rest of Europe, 2021-2031, $ mn
Figure 65. Asia-Pacific Minimal Residual Disease Testing Market, 2021-2031, $ mn
Figure 66. Breakdown of APAC Minimal Residual Disease Testing Market by Country, 2021 and 2031, % of Revenue
Figure 67. Contribution to APAC 2022-2031 Cumulative Market by Country, Value ($ mn) and Share (%)
Figure 68. Minimal Residual Disease Testing Market in Japan, 2021-2031, $ mn
Figure 69. Minimal Residual Disease Testing Market in China, 2021-2031, $ mn
Figure 70. Minimal Residual Disease Testing Market in Australia, 2021-2031, $ mn
Figure 71. Minimal Residual Disease Testing Market in India, 2021-2031, $ mn
Figure 72. Minimal Residual Disease Testing Market in South Korea, 2021-2031, $ mn
Figure 73. Minimal Residual Disease Testing Market in Rest of APAC, 2021-2031, $ mn
Figure 74. South America Minimal Residual Disease Testing Market, 2021-2031, $ mn
Figure 75. Breakdown of South America Minimal Residual Disease Testing Market by Country, 2021 and 2031, % of Revenue
Figure 76. Contribution to South America 2022-2031 Cumulative Market by Country, Value ($ mn) and Share (%)
Figure 77. Minimal Residual Disease Testing Market in Argentina, 2021-2031, $ mn
Figure 78. Minimal Residual Disease Testing Market in Brazil, 2021-2031, $ mn
Figure 79. Minimal Residual Disease Testing Market in Chile, 2021-2031, $ mn
Figure 80. Minimal Residual Disease Testing Market in Rest of South America, 2021-2031, $ mn
Figure 81. Minimal Residual Disease Testing Market in Middle East and Africa (MEA), 2021-2031, $ mn
Figure 82. Breakdown of MEA Minimal Residual Disease Testing Market by Country, 2021 and 2031, % of Revenue
Figure 83. Contribution to MEA 2022-2031 Cumulative Market by Country, Value ($ mn) and Share (%)
Figure 84. Minimal Residual Disease Testing Market in UAE, 2021-2031, $ mn
Figure 85. Minimal Residual Disease Testing Market in Saudi Arabia, 2021-2031, $ mn
Figure 86. Minimal Residual Disease Testing Market in South Africa, 2021-2031, $ mn
Figure 87. Growth Stage of Global Minimal Residual Disease Testing Industry over the Forecast Period
Companies Mentioned
A selection of companies mentioned in this report includes:
- Adaptive Biotechnologies Corporation
- ArcherDX, Inc. (Invitae Corporation)
- Arup Laboratories
- Asuragen Inc.
- Bio-Rad Laboratories, Inc.
- Cergentis B.V.
- Guardant Health
- ICON plc
- Inivata Ltd.
- Invivoscribe, Inc.
- Laboratory Corporation of America Holdings
- Mission Bio, Inc.
- Natera, Inc.
- NeoGenomics Laboratories, Inc.
- Opko Health, Inc.
- Quest Diagnostics Incorporated
- Sysmex Corporation
Methodology
LOADING...
